{Reference Type}: Journal Article
{Title}: NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022.
{Author}: Wierda WG;Brown J;Abramson JS;Awan F;Bilgrami SF;Bociek G;Brander D;Chanan-Khan AA;Coutre SE;Davis RS;Eradat H;Fletcher CD;Gaballa S;Ghobadi A;Hamid MS;Hernandez-Ilizaliturri F;Hill B;Kaesberg P;Kamdar M;Kaplan LD;Khan N;Kipps TJ;Ma S;Mato A;Mosse C;Schuster S;Siddiqi T;Stephens DM;Ujjani C;Wagner-Johnston N;Woyach JA;Ye JC;Dwyer MA;Sundar H;
{Journal}: J Natl Compr Canc Netw
{Volume}: 20
{Issue}: 6
{Year}: 06 2022
{Factor}: 12.693
{DOI}: 10.6004/jnccn.2022.0031
{Abstract}: The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/SLL specific to the use of chemotherapy-free treatment options for patients with treatment-naïve and relapsed/refractory disease.